HWP
CRL icon

Highline Wealth Partners’s Charles River Laboratories CRL Stock Holding History

Highline Wealth Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Sell
5
-2
-29% -$356 ﹤0.01% 1255
2026
Q1 		$1.21K Buy
+7
New +$1.3K ﹤0.01% 1131

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Highline Wealth Partners's CRL Position: Q2 2026 in Review

Highline Wealth Partners reduced its Charles River Laboratories (CRL) stake by 29% in Q2 2026, selling an estimated $356 and leaving 5 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Highline Wealth Partners first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.21K in Q1 2026. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Highline Wealth Partners held 5 shares of Charles River Laboratories worth $1.13K as of Q2 2026.
  • Highline Wealth Partners sold 2 Charles River Laboratories shares in Q2 2026, an estimated $356.
  • Charles River Laboratories made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #1255 holding.
  • Highline Wealth Partners first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • Highline Wealth Partners's Charles River Laboratories position peaked at $1.21K in Q1 2026.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.